Effectiveness of Wobenzym in combined therapy of chronic bacterial prostatitis. Results of systematic review and meta-analysis

Abstract

A systematic review and meta-analysis of research data on the effectiveness of the drug Wobenzym in the treatment of chronic bacterial prostatitis was performed. The aim of this study to evaluate the effectiveness of Wobenzym in the complex therapy of chronic bacterial prostatitis. The analysis included randomized and non-randomized controlled studies of the effectiveness of Wobenzim in the complex therapy of chronic bacterial prostatitis. The search was carried out in the databases CENTRAL, PubMed, ICTRP, eLibrary, ClinicalTrials.gov., Google Scholar, CyberLeninka, search engines. The meta-analysis was conducted using the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions. Statistical heterogeneity was assessed using the Cochran test and visually when constructing forest plots. A random effects model and a fixed effect model were used. Works published over the entire period were analyzed, 712 publications were identified, of which 9 fully met the stated criteria, all studies were non-randomized controlled. The final analysis included the results of 1292 patients. According to the meta-analysis, it was possible to establish the superiority of complex therapy including Wobenzym compared to therapy without Wobenzym in all studied parameters: eradication of the pathogen, decrease in the number of points on the Quality of Life (QoL) scale, an increase in the linear speed of blood flow in the veins and peak systolic blood flow velocity in the arteries of the prostate gland, maximum urine flow rate, reduction in the number of points of the NIH-CPSI “Pain” subscale (difference 5 points) and NIH-CPSI “Quality of Life” subscale. The use of therapy including Wobenzym in patients with chronic prostatitis leads to a greater increase in the number of CD4+, CD8+ lymphocytes, phagocytic activity of lymphocytes, the level of complement CH-100 and immunoglobulins M, G, A. A systematic review/meta-analysis revealed an objective, statistically significant, positive effect of the drug Wobenzym in the complex therapy of patients with chronic bacterial prostatitis, which is associated with its pathogenetic orientation in relation to this group of patients.

Keywords

chronic bacterial prostatitis / Wobenzym / meta-analysis

References

[1] Suvorov S, Tolstokorov S. Optimization of therapy of patients with chronic uretrogenic prostatitis. Universum: Medicine and pharmacology. 2019;(9):10–12. EDN: SXUBHX

[2] Суворов С.А., Толстокоров С.А. Оптимизация терапии больных хроническим уретрогенным простатитом // Universum: Медицина и фармакология. 2019. № 9. С. 10–12. EDN: SXUBHX

[3] Vermassen T, Van Praet C, Poelaert F, et al. Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis. Biochem Med (Zagreb). 2015;25(3):439–449. doi: 10.11613/BM.2015.045

[4] Vermassen T., Van Praet C., Poelaert F., et al. Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis // Biochem Med (Zagreb). 2015. Vol. 25, N. 3. P. 439–449. doi: 10.11613/BM.2015.045

[5] Kwan ACF, Beahm NP. Fosfomycin for bacterial prostatitis: a review. Int J Antimicrob Agents. 2020;56(4):106106. doi: 10.1016/j.ijantimicag.2020.106106

[6] Kwan A.C.F., Beahm N.P. Fosfomycin for bacterial prostatitis: a review // Int J Antimicrob Agents. 2020. Vol. 56, N. 4. ID 106106. doi: 10.1016/j.ijantimicag.2020.106106

[7] Pushkar DYu, Rasner PI, Kotenko DV, et al. Specific features of lower urinary tract symptoms in men living in the Moscow Region. Results of the epidemiological study. Urologiia. 2018;(3):20–29. EDN: UVCSAJ doi: 10.18565/urology.2018.3.20-28

[8] Пушкарь Д.Ю., Раснер П.И., Котенко Д.В., и др. Особенности симптомов нижних мочевыводящих путей у мужчин Московского региона. Результаты эпидемиологического исследования // Урология. 2018. № 3. С. 20–29. EDN: UVCSAJ doi: 10.18565/urology.2018.3.20-28

[9] Suskind AM, Berry SH, Ewing BA, et al. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: Results of the RAND Interstitial cystitis epidemiology male study. J Urol. 2013;189(1):141–145. doi: 10.1016/j.juro.2012.08.088

[10] Suskind A.M., Berry S.H., Ewing B.A., et al. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: Results of the RAND Interstitial cystitis epidemiology male study // J Urol. 2013. Vol. 189, N. 1. P. 141–145. doi: 10.1016/j.juro.2012.08.088

[11] Panchenko IA, Brusnev AB, Garmash ON, et al. Men’s reproductive service based on the regional specialized center. Experimental and clinical urology. 2019;(2):20–25. EDN: QARIIS doi: 10.29188/2222-8543-2019-11-2-20-24

[12] Панченко И.А., Бруснев А.Б., Гармаш О.Н., и др. Служба репродуктивного мужского здоровья на примере краевого специализированного центра // Экспериментальная и клиническая урология. 2019. № 2. С. 20–25. EDN: QARIIS doi: 10.29188/2222-8543-2019-11-2-20-24

[13] Shoskes DA, Nickel JC, Rackley RR, Pontari MA. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis. 2009;12(2):177–183. doi: 10.1038/pcan.2008.42

[14] Shoskes D.A., Nickel J.C., Rackley R.R., Pontari M.A. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes // Prostate Cancer Prostatic Dis. 2009. Vol. 12, N. 2. P. 177–183. doi: 10.1038/pcan.2008.42

[15] Filimonov PN, Kulchavenya EV. Consequences of excessive fibrosis formation in patients with chronic prostatitis. RMJ. 2019;27(2):39–41. EDN: UDLZTH

[16] Филимонов П.Н., Кульчавеня Е.В. Последствия избыточного формирования фиброза у больных хроническим простатитом // РМЖ. 2019. Т. 27, № 2. С. 39–41. EDN: UDLZTH

[17] Bouiller K, Zayet S, Lalloz PE, et al. Efficacy and safety of oral fosfomycin-trometamol in male urinary tract infections with multidrug-resistant enterobacterales. Antibiotics (Basel). 2022;11(2):198. doi: 10.3390/antibiotics11020198

[18] Bouiller K., Zayet S., Lalloz P.E., et al. Efficacy and safety of oral fosfomycin-trometamol in male urinary tract infections with multidrug-resistant enterobacterales // Antibiotics (Basel). 2022. Vol. 11, N. 2. ID198. doi: 10.3390/antibiotics11020198

[19] Shormanov IS, Solov’ev AS. Pathogenic mechanisms of pain in chronic bacterial prostatitis. Experimental and clinical urology. 2016;(3):96–101. EDN: YHTWRP

[20] Шорманов И.С., Соловьев А.С. Патогенетические механизмы болевого синдрома при хроническом бактериальном простатите // Экспериментальная и клиническая урология. 2016. № 3. С. 96–101. EDN: YHTWRP

[21] Smelov V, Perekalina T, Artemenko N, et al. Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome. Andrologia. 2005;37(2–3):61–64. doi: 10.1111/j.1439-0272.2005.00654.x

[22] Smelov V., Perekalina T., Artemenko N., et al. Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome // Andrologia. 2005. Vol. 37, N. 2–3. P. 61–64. doi: 10.1111/j.1439-0272.2005.00654.x

[23] uroweb.org [Internet]. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan, Italy 2023. Available from: https://uroweb.org/guidelines/urological-infections

[24] uroweb.org [Электронный ресурс]. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan, Italy 2023. Режим доступа: https://uroweb.org/guidelines/urological-infections

[25] Wagenlehner FME, Naber KG. Prostatitis: the role of antibiotic treatment. World J Urol. 2003;21(2):105–108. doi: 10.1007/s00345-003-0333-4

[26] Wagenlehner F.M.E., Naber K.G. Prostatitis: the role of antibiotic treatment // World J Urol. 2003. Vol. 21, N. 2. P. 105–108. doi: 10.1007/s00345-003-0333-4

[27] Hu M, Wazir J, Ullah R, et al. Phytotherapy and physical therapy in the management of chronic prostatitis-chronic pelvic pain syndrome. Int Urol Nephrol. 2019;51(7):1081–1088. doi: 10.1007/s11255-019-02161-x

[28] Hu M., Wazir J., Ullah R., et al. Phytotherapy and physical therapy in the management of chronic prostatitis-chronic pelvic pain syndrome // Int Urol Nephrol. 2019. Vol. 51, N. 7. P. 1081–1088. doi: 10.1007/s11255-019-02161-x

[29] Dosta NI, Sevostianov NS. Efficiency of application enzymotherapy in complex treatment of a chronic bacterial prostatitis. Medical News. 2013;(12):72–76. EDN: RRSUBL

[30] Доста Н.И., Севостьянов Н.С. Эффективность применения энзимотерапии в комплексном лечении хронического бактериального простатита // Медицинские новости. 2013. № 12. С. 72–76. EDN: RRSUBL

[31] Sternin YI, Tetz BB, Knorring GYu. Modern possibilities of optimization of antibacterial therapy. Glavnyi vrach uga Russia. 2010;(3):17–20. EDN: XGIAJY (In Russ.)

[32] Стернин Ю.И., Тец В.В., Кнорринг Г.Ю. Современные возможности оптимизации антибактериальной терапии // Главный врач Юга России. 2010. № 3. С. 17–20. EDN: XGIAJY

[33] Mikhailov IB, Sternin YuI. Selected issues of clinical pharmacology of systemic enzymotherapy. Archive of Internal Medicine. 2012;(1): 15–19. EDN: RPEMEH doi: 10.20514/2226-6704-2012-0-1-15-19

[34] Михайлов И.Б., Стернин Ю.И. Избранные вопросы клинической фармакологии системной энзимотерапии // Архивъ внутренней медицины. 2012. № 1. С. 15–19. EDN: RPEMEH doi: 10.20514/2226-6704-2012-0-1-15-19

[35] Higgins J, Thomas J, editors. Cochrane handbook for systematic reviews of interventions. Available from: https://training.cochrane.org/handbook/current

[36] Higgins J., Thomas J., editors. Cochrane handbook for systematic reviews of interventions. Режим доступа: https://training.cochrane.org/handbook/current

[37] Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions: Cochrane book series. Chichester, England: Hoboken, New Jersey: Wiley-Blackwell, 2008. 649 p. doi: 10.1002/9780470712184

[38] Cochrane handbook for systematic reviews of interventions: Cochrane book series / edit by J.P.T. Higgins, S. Green. Chichester, England: Hoboken, New Jersey: Wiley-Blackwell, 2008. 649 p. doi: 10.1002/9780470712184

[39] Rebrova OYu, Fedyaeva VK, Khachatryan GR. Adaptation and validation of the cochrane questionnarie to assess risks of bias in randomized controlled trials. Medical technologies. Assessment and choice. 2015;(1):9–17. EDN: RYRKUT

[40] Реброва О.Ю., Федяева В.К., Хачатрян Г.Р. Адаптация и валидизация вопросника для оценки риска систематических ошибок в рандомизированных контролируемых испытаниях // Медицинские технологии. Оценка и выбор. 2015. № 1. С. 9–17. EDN: RYRKUT

[41] sites.google.com [Internet]. Risk of bias tools — robvis (visualization tool). Available from: https://sites.google.com/site/riskofbiastool/welcome/robvis-visualization-tool

[42] sites.google.com [Электронный ресурс]. Risk of bias tools — robvis (visualization tool). Режим доступа: https://sites.google.com/site/riskofbiastool/welcome/robvis-visualization-tool

[43] gdt.gradepro.org [Internet]. GRADE handbook. Available from: https://gdt.gradepro.org/app/handbook/handbook.html

[44] gdt.gradepro.org [Электронный ресурс]. GRADE handbook. Режим доступа: https://gdt.gradepro.org/app/handbook/handbook.html

[45] www.prisma-statement.org [Internet]. PRISMA flow diagram. Available from: http://www.prisma-statement.org/PRISMAStatement/FlowDiagram

[46] www.prisma-statement.org [Электронный ресурс]. PRISMA flow diagram. Режим доступа: http://www.prisma-statement.org/PRISMAStatement/FlowDiagram

[47] Dzhalilov HN, Arbuliev KM, Dzhalilova DN, Gusniev NM. Improving medical and social rehabilitation of elderly patients and older with chronic bacterial prostatitis. Ural Medical Journal. 2020;(2):115–120. EDN: CRWPEB doi: 10.25694/URMJ.2020.02.28

[48] Джалилов Х.Н., Арбулиев К.М., Джалилова Д.Н., Гусниев Н.М. Совершенствование медико-социальной реабилитации пациентов пожилого возраста и старше с хроническим бактериальным простатитом // Уральский медицинский журнал. 2020. № 2. С. 115–120. EDN: CRWPEB doi: 10.25694/URMJ.2020.02.28

[49] Ershov EV. Evaluation of prostate blood circulation in patients with chronic prostatitis. Nephrology (Saint-Petersburg). 2007;11(1):103–107. EDN: HZGOLV

[50] Ершов Е.В. Оценка кровообращения в предстательной железе у больных хроническим простатитом // Нефрология. 2007. Т. 11, № 1. С. 103–107. EDN: HZGOLV

[51] Kodiri TR, Saydulloev L, Sayfulloev KU, et al. Efficacy of vobenzyme in the treatment of chronic prostatitis. Scientific and Practical Journal of TIPPMC. 2013;(2):160–161. EDN: RHMRQZ (In Russ.)

[52] Кодири Т.Р., Сайдуллоев Л., Сайфуллоев К.У., и др. Эффективность Вобэнзима при лечении хронического простатита // Научно-практический журнал ТИППМК. 2013. № 2. С. 160–161. EDN: RHMRQZ

[53] Noskov NYu. Use of vobenzyme in complex therapy of patients with chronic prostatitis. Nephrology (Saint Petersburg). 2004;8(3):84–86. EDN: JUKPJL doi: 10.24884/1561-6274-2004-8-3-84-86

[54] Носков Н.Ю. Применение Вобэнзима в комплексной терапии больных хроническим простатитом // Нефрология. 2004. Т. 8, № 3. С. 84–86. EDN: JUKPJL doi: 10.24884/1561-6274-2004-8-3-84-86

[55] Tkachuk VN, Al-Shukri AS, Tkachuk IN, Sternin YI. The results of a 10-year efficacy study of proteolytic enzymes in patients with chronic prostatitis. Urology reports (St. Petersburg). 2015;5(2):5–9. EDN: UKKJOV doi: 10.17816/uroved525-9

[56] Ткачук В.Н., Аль-Шукри А.С., Ткачук И.Н., Стернин Ю.И. Результаты 10-летнего исследования эффективности протеолитических энзимов у больных хроническим простатитом // Урологические ведомости. 2015. Т. 5, № 2. С. 5–9. EDN: UKKJOV doi: 10.17816/uroved525-9

[57] Tkachuk VN, Lukyanov AE, Noskov NY. Place of systemic enzymotherapy in complex treatment of patients with chronic prostatitis. Physician’s estate. 2007;(5):36–41. (In Russ.)

[58] Ткачук В.Н., Лукьянов А.Э., Носков Н.Ю. Место системной энзимотерапии в комплексном лечении больных хронически простатитом // Врачебное сословие. 2007. № 5. С. 36–41.

[59] Solihov DN. Vobenzyme in the treatment of chronic bacterial prostatitis. DAN of the Republic of Tajikistan. 2009;52(5):400–402. (In Russ.)

[60] Солихов Д.Н. Вобэнзим в лечении хронического бактериального простатита // ДАН Республики Таджикистан. 2009. Т. 52, № 5. С. 400–402.

[61] Dzhalilov KhN, Arbuliev KM, Saidov MS, et al. To the question of the use of drugs with a polymodal effect in the complex treatment of elderly and senile patients with recurrent chronic bacterial prostatitis. Ural Medical Journal. 2019;(15):154–160. EDN: PZVUCB doi: 10.25694/URMJ.2019.15.32

[62] Джалилов Х.Н., Арбулиев К.М., Саидов М.С., и др. К вопросу об использовании препаратов с полимодальным действием в комплексной терапии пациентов пожилого и старческого возраста с рецидивирующим хроническим бактериальным простатитом // Уральский медицинский журнал. 2019. № 15. С. 154–160. EDN: PZVUCB doi: 10.25694/URMJ.2019.15.32

RIGHTS & PERMISSIONS

Eco-Vector